Evidence map›Paper›PMID 41152936›Full record

ReviewJournal of cardiothoracic surgery2025

Knowledge domain and emerging trends on the SGLT2 inhibitor dapagliflozin for heart failure: a bibliometric analysis from 2012 to 2024.

Mengxuan Xiao, Yuan Sui, Daoyao Fu, Shaolin Gong, Nana Xiong, Yifan Wu, Wenjun Xiong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengxuan XiaoDepartment of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, China.
Yuan SuiDepartment of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, China.
Daoyao FuDepartment of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, China.
Shaolin GongDepartment of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, China.
Nana XiongDepartment of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, China.
Yifan WuDepartment of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, China.
Wenjun XiongDepartment of Cardiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, 17 Yongwaizheng Street, Nanchang, 330006, Jiangxi, China. wenjunxiong@ncu.edu.cn.

Funding

Natural Science Foundation of Jiangxi, China 20224BAB216016
6 · The paper itself

Abstract

purposeDapagliflozin has been formally used to treat heart failure on the basis of extensive data from the DAPA-HF trial, and it now serves as a new quadruple cornerstone drug for heart failure. This study aimed to understand the global research hotspots and trends in dapagliflozin treatment for heart failure through bibliometric analysis and to provide directions for future research.

methodsAll literature on dapagliflozin for heart failure was collected from the Web of Science Core Collection (WOSCC) between January 1, 2012, and January 1, 2024. Bibliometric analysis of the retrieved data was performed using CiteSpace and Bibliometrix (R package).

resultsA total of 919 publications were retrieved, involving 215 authors, 216 institutions, and 76 countries/regions. Since 2016, the annual number of publications on dapagliflozin for heart failure has demonstrated a consistent upward trend. The most prolific authors include Anna Maria Langkilde, Mikhail N. Kosiborod, and Scott D. Solomon. The top contributing countries were the United States, Sweden, and China, while the leading institutions were AstraZeneca, Harvard University, and Brigham and Women’s Hospital. Keyword analysis revealed that treatment for diverse heart failure subtypes, cardiorenal outcomes, combination therapies, and underlying mechanisms have emerged as prominent research foci.

conclusionBased on our findings, future investigations are expected to focus on dapagliflozin’s therapeutic potential for heart failure with preserved ejection fraction (HFpEF), particularly regarding combination therapy with novel non-steroidal mineralocorticoid receptor antagonists (MRAs). Additionally, the mechanism underlying dapagliflozin’s anti-fibrotic effects requires further mechanistic investigation.

Indexed as

Benzhydryl CompoundsBibliometricsGlucosidesHeart FailureSodium-Glucose Transporter 2 InhibitorsHumansBenzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsBibliometricCiteSpaceDapagliflozinHeart failure

Identifiers

PMID41152936
PMCPMC12570410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.